Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Palliative chemotherapy (PC) is not standardized for patients with advanced ampulla of Vater adenocarcinoma (AA). This multicenter, retrospective study evaluated first-line PC outcomes in patients with AA. Methods: Patients diagnosed with AA between January 2010 and December 2020 who underwent PC were enrolled from 10 institutions. Overall survival (OS) and progression-free survival (PFS) according to the chemotherapy regimen were analyzed. Results: Of 255 patients (mean age, 64.0±10.0 years; male, 57.6%), 14 (5.5%) had locally advanced AA and 241 (94.5%) had metastatic AA. Gemcitabine plus cisplatin (GP) was administered as first-line chemotherapy to 192 patients (75.3%), whereas capecitabine plus oxaliplatin (CAPOX) was administered to 39 patients (15.3%). The median OS of all patients was 19.8 months (95% confidence interval [CI], 17.3 to 22.3), and that of patients who received GP and CAPOX was 20.4 months (95% CI, 17.2 to 23.6) and 16.0 months (95% CI, 11.2 to 20.7), respectively. The median PFS of GP and CAPOX patients were 8.4 months (95% CI, 7.1 to 9.7) and 5.1 months (95% CI, 2.5 to 7.8), respectively. PC for AA demonstrated improved median outcomes in both OS and PFS compared to conventional bile duct cancers that included AA. Conclusions: While previous studies have shown mixed prognostic outcomes when AA was analyzed together with other biliary tract cancers, our study unveils a distinct clinical prognosis specific to AA on a large scale with systemic anticancer therapy. These findings suggest that AA is a distinct type of tumor, different from other biliary tract cancers, and AA itself could be expected to have a favorable response to PC.
Abstract
Background/Aims: Palliative chemotherapy (PC) is not standardized for patients with advanced ampulla of Vater adenocarcinoma (AA). This multicenter, retrospective study evaluated first-line PC outcomes in patients with AA. Methods: Patients diagnosed with AA between January 2010 and December 2020 who underwent PC were enrolled from 10 institutions. Overall survival (OS) and progression-free survival (PFS) according to the chemotherapy regimen were analyzed. Results: Of 255 patients (mean age, 64.0±10.0 years; male, 57.6%), 14 (5.5%) had locally advanced AA and 241 (94.5%) had metastatic AA. Gemcitabine plus cisplatin (GP) was administered as first-line chemotherapy to 192 patients (75.3%), whereas capecitabine plus oxaliplatin (CAPOX) was administered to 39 patients (15.3%). The median OS of all patients was 19.8 months (95% confidence interval [CI], 17.3 to 22.3), and that of patients who received GP and CAPOX was 20.4 months (95% CI, 17.2 to 23.6) and 16.0 months (95% CI, 11.2 to 20.7), respectively. The median PFS of GP and CAPOX patients were 8.4 months (95% CI, 7.1 to 9.7) and 5.1 months (95% CI, 2.5 to 7.8), respectively. PC for AA demonstrated improved median outcomes in both OS and PFS compared to conventional bile duct cancers that included AA. Conclusions: While previous studies have shown mixed prognostic outcomes when AA was analyzed together with other biliary tract cancers, our study unveils a distinct clinical prognosis specific to AA on a large scale with systemic anticancer therapy. These findings suggest that AA is a distinct type of tumor, different from other biliary tract cancers, and AA itself could be expected to have a favorable response to PC.
참고문헌 (34)
- Hong SS, "Comparison of oncologic outcomes between transduodenal ampullectomy and pancreatoduodenectomy in ampulla of Vater cancer : Korean Multicenter Study", Cancers(Basel), 13, pp.2038~ (2021)
- Ahn DH, "Ampullary cancer : an overview", Am Soc Clin Oncol Educ Book, pp.112~115 (2014)
- Zheng-Pywell R, "Ampullary cancer", Surg Clin North Am, 99, pp.357~367 (2019)
- O’Connell JB, "Survival after resection of ampullary carcinoma : a national populationbased study", Ann Surg Oncol, 15, pp.1820~1827 (2008)
- Bouvet M, "Factors influencing survival after resection for periampullary neoplasms", Am J Surg, 180, pp.13~17 (2000)
- van Geenen RC, "Survival after pancreaticoduodenectomy for periampullary adenocarcinoma : an update", Eur J Surg Oncol, 27, pp.549~557 (2001)
- Woo SM, "Recurrence and prognostic factors of ampullary carcinoma after radical resection : comparison with distal extrahepatic cholangiocarcinoma", Ann Surg Oncol, 14, pp.3195~3201 (2007)
- Czaykowski P, "Chemotherapy in small bowel adenocarcinoma : 10-year experience of the British Columbia Cancer Agency", Clin Oncol(R Coll Radiol), 19, pp.143~149 (2007)
- Kohler I, "Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications", Am J Clin Pathol, 135, pp.202~211 (2011)
- Westgaard A, "Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma", BMC Cancer, 8, pp.170~ (2008)
- Ruemmele P, "Histopathologic features and microsatellite instability of cancers of the papilla of Vater and their precursor lesions", Am J Surg Pathol, 33, pp.691~704 (2009)
- Fischer HP, "Pathogenesis of carcinoma of the papilla of Vater", J Hepatobiliary Pancreat Surg, 11, pp.301~309 (2004)
- Zhou H, "Carcinoma of the ampulla of Vater : comparative histologic", immunohistochemical classification and follow-up, 2004, pp.28, 875~882
- Roh YH, "The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma : the intestinal type is associated with a better prognosis", Hepatogastroenterology, 54, pp.1641~1644 (2007)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- Okusaka T, "Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan", Br J Cancer, 103, pp.469~474 (2010)
- Leone F, "Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer : a randomized phase 2 trial(Vecti-BIL study)", Cancer, 122, pp.574~581 (2016)
- Malka D, "Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer(BINGO) : a randomised, open-label, non-comparative phase 2 trial", Lancet Oncol, 15, pp.819~828 (2014)
- Lee J, "Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer : a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 13, pp.181~188 (2012)
- Sharma A, "A phase II study of gemcitabine and oxaliplatin(Oxigem)in unresectable gall bladder cancer", Cancer Chemother Pharmacol, 65, pp.497~502 (2010)
- André T, "Gemcitabine and oxaliplatin in advanced biliary tract carcinoma : a phase II study", Br J Cancer, 99, pp.862~867 (2008)
- Jung K, "Realworld outcomes of gemcitabine, cisplatin, and nab-paclitaxel chemotherapy regimen for advanced biliary tract cancer : a propensity score-matched analysis", Gut Liver, 16, pp.798~805 (2022)
- Kwon SC, "The Expression of programmed death-ligand 1 on immune cells is related to a better prognosis in biliary tract cancer", Gut Liver, 17, pp.933~941 (2023)
- Jiang ZQ, "A retrospective study of ampullary adenocarcinomas : overall survival and responsiveness to fluoropyrimidine-based chemotherapy", Ann Oncol, 24, pp.2349~2353 (2013)
- Overman MJ, "Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater", J Clin Oncol, 27, pp.2598~2603 (2009)
- Morizane C, "Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced", recurrent biliary tract cancer : the FUGA-BT(JCOG1113)randomized phase III clinical trial, 2019, pp.30, 1950~1958
- Perkins G, "Can we classify ampullary tumours better? Clinical, pathological and molecular features: results of an AGEO study", Br J Cancer, 120, pp.697~702 (2019)
- Kim WS, "Clinical significance of pathologic subtype in curatively resected ampulla of Vater cancer", J Surg Oncol, 105, pp.266~272 (2012)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Westgaard A, "Intestinal-type and pancreatobiliary-type adenocarcinomas : how does ampullary carcinoma differ from other periampullary malignancies?", Ann Surg Oncol, 20, pp.430~439 (2013)
- Hansel DE, "Expression of the caudaltype homeodomain transcription factors CDX 1", 2 and outcome in carcinomas of the ampulla of Vater, 2005, pp.23, 1811~1818
- Gingras MC, "Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation", Cell Rep, 14, pp.907~919 (2016)
- Yachida S, "Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma", Cancer Cell, 29, pp.229~240 (2016)
- Mafficini A, "Ampulla of Vater carcinoma : sequencing analysis identifies TP53 status as a novel independent prognostic factor and potentially actionable ERBB, PI3K, and WNT pathways gene mutations", Ann Surg, 267, pp.149~156 (2018)